Literature DB >> 7635561

Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE).

D Ford1, J M Bliss, A J Swerdlow, B K Armstrong, S Franceschi, A Green, E A Holly, T Mack, R M MacKie, A Osterlind.   

Abstract

In a combined analysis of 2952 melanoma patients and 3618 controls from 8 case-control studies in white populations the risk of cutaneous melanoma was 2.24-fold higher (95% CI, 1.76-2.86) in subjects who reported at least one affected first-degree relative than in subjects who did not. There was no evidence for heterogeneity in the relative risk between the studies, which were from a wide range of latitudes and hence degrees of sun exposure. The effect of family history on melanoma risk was independent of age, naevus count, hair and eye colour, and freckling. There was no evidence for a relationship between family history and primary site of melanoma but there was some suggestion that the familial patients were more likely to have superficial spreading melanoma or lentigo maligna melanoma than acral lentiginous melanoma or nodular melanoma.

Entities:  

Mesh:

Year:  1995        PMID: 7635561     DOI: 10.1002/ijc.2910620403

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

1.  Personal attributions for melanoma risk in melanoma-affected patients and family members.

Authors:  Jennifer Hay; Marco DiBonaventura; Raymond Baser; Nancy Press; Jeanne Shoveller; Deborah Bowen
Journal:  J Behav Med       Date:  2010-09-01

2.  A hierarchical frailty model applied to two-generation melanoma data.

Authors:  Tron Anders Moger; Marion Haugen; Benjamin H K Yip; Håkon K Gjessing; Ornulf Borgan
Journal:  Lifetime Data Anal       Date:  2010-11-04       Impact factor: 1.588

3.  Factors associated with inconsistent sun protection in first-degree relatives of melanoma survivors.

Authors:  Elyse Shuk; Jack E Burkhalter; Carlos F Baguer; Susan M Holland; Alisa Pinkhasik; Mary Sue Brady; Daniel G Coit; Charlotte E Ariyan; Jennifer L Hay
Journal:  Qual Health Res       Date:  2012-07

4.  Visual screening for malignant melanoma: a cost-effectiveness analysis.

Authors:  Elena Losina; Rochelle P Walensky; Alan Geller; Frederick C Beddingfield; Lindsey L Wolf; Barbara A Gilchrest; Kenneth A Freedberg
Journal:  Arch Dermatol       Date:  2007-01

5.  Tailored versus generic interventions for skin cancer risk reduction for family members of melanoma patients.

Authors:  Sharon Manne; Paul B Jacobsen; Michael E Ming; Gary Winkel; Sophie Dessureault; Stuart R Lessin
Journal:  Health Psychol       Date:  2010-11       Impact factor: 4.267

6.  Family communication after melanoma diagnosis.

Authors:  Jennifer Hay; Elyse Shuk; Mary S Brady; Marianne Berwick; Jamie Ostroff; Allan Halpern
Journal:  Arch Dermatol       Date:  2008-04

7.  Alcohol consumption and risk of melanoma among women: pooled analysis of eight case-control studies.

Authors:  Kyoko Miura; Michael S Zens; Tessa Peart; Elizabeth A Holly; Marianne Berwick; Richard P Gallagher; Thomas M Mack; J Mark Elwood; Margaret R Karagas; Adèle C Green
Journal:  Arch Dermatol Res       Date:  2015-07-16       Impact factor: 3.017

Review 8.  [Meta-analysis of epidemiologic studies].

Authors:  M Blettner; W Sauerbrei
Journal:  Med Klin (Munich)       Date:  1998-07-15

9.  Randomized controlled trial of a sun protection intervention for children of melanoma survivors.

Authors:  Ellen R Gritz; Mary K Tripp; Susan K Peterson; Alexander V Prokhorov; Sanjay S Shete; Diana L Urbauer; Bryan M Fellman; Jeffrey E Lee; Jeffrey E Gershenwald
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10       Impact factor: 4.254

10.  Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients.

Authors:  Haike M J van der Velden; Michelle M van Rossum; Willeke A M Blokx; Jan B M Boezeman; Marie-Jeanne P Gerritsen
Journal:  Dermatol Res Pract       Date:  2009-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.